End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
1,420 IDR | -1.73% | -2.41% | -11.80% |
Apr. 30 | PT Kalbe Farma Tbk. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 01 | PT Kalbe Farma Tbk. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Strengths
- The company is in a robust financial situation considering its net cash and margin position.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.80% | 4.16B | B+ | ||
+32.95% | 700B | C+ | ||
-4.97% | 358B | C+ | ||
+18.83% | 330B | B- | ||
+3.54% | 287B | C+ | ||
+15.70% | 236B | B+ | ||
+6.68% | 202B | B- | ||
-9.08% | 197B | A+ | ||
+6.70% | 161B | C+ | ||
-1.81% | 157B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- KLBF Stock
- Ratings PT Kalbe Farma Tbk.